Pharma in review: trending stories 8/23/19
Pfizer recalls migraine drug for possible microbial contamination
Pfizer has recalled two lots of migraine drug Relpax.
FDA warns Chinese co. for data integrity violations
The agency posted a warning letter to Ningbo Huize Commodity, an OTC drug manufacturer.
The agency posted a warning letter to Ningbo Huize Commodity, an OTC drug manufacturer.
AbbVie’s Humira follow-up gets FDA nod
A potential new blockbuster from AbbVie has gotten the go-ahead from the FDA.
FDA rejects potential jet lag treatment
Vanda Pharma announced that it has received a complete response letter from the FDA for Hetlioz.
Celgene wins key FDA ok ahead of BMS merger
The U.S. FDA has approved Celgene's rare bone marrow cancer drug, Inrebic.